23 February 2024 - Positive CHMP opinion is based on pivotal Phase 3 PROTECT study results. ...
23 February 2024 - The EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting. ...
23 February 2024 - The EMA has recommended granting a marketing authorisation in the European Union for Voydeya, the first ...
23 February 2024 - In the pivotal Phase 3 COMMANDS study, Reblozyl nearly doubled the percentage of patients achieving primary ...
23 February 2024 - Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial. ...
23 February 2024 - Late last year, many of my colleagues returned from the largest international gathering of doctors who ...
22 February 2024 - Thousands of people with severe hair loss due to alopecia areata are set to benefit from a ...
22 February 2024 - Australia risks “being pushed to the back of the queue” of countries to gain access to ...
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
19 February 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...
15 February 2024 - The draft paper 'Emerging Health Technologies' developed to support the deliberations of the HTA Review Reference ...
12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
12 February 2024 - The U.S. House of Representatives passed H.R. 485, the Protecting Health Care for All Patients Act, this ...
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone ...